CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma
- PMID: 33612309
- DOI: 10.1016/j.jhep.2021.01.030
CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.J Hepatol. 2021 May;74(5):1145-1154. doi: 10.1016/j.jhep.2020.11.037. Epub 2020 Dec 1. J Hepatol. 2021. PMID: 33276030 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials